Quarterly report available here
ir.targen.com
I see that the enterprise value (as reported
by Yahoo) is about minus half a million.
As of March 31, 2008, our accumulated deficit
totaled $303.6 million
Here is the stuff TGEN highlighted for the quarter:
In April 2008, the Company announced encouraging results from a Phase
1/2 clinical study demonstrating that treatment of three young adults with
Leber's congenital amaurosis (LCA) with an AAV vector containing the RPE 65
coding sequence resulted in improved visual function in one patient. The
study, titled "Effect of Gene Therapy on Visual Function in Leber's
Congenital Amaurosis," by Bainbridge, et al., conducted in collaboration
with University College London and Moorfields Hospital, will appear in the
May 22, 2008 issue of the New England Journal of Medicine.
-- In April 2008, preclinical data characterizing the novel use of AAV
vectors to deliver small interfering RNA (siRNA) for the treatment of
Huntington's disease were published in the April 15th issue of Proceedings
of the National Academy of Sciences of the United States of America.
-- In April 2008, the Company acquired full exclusive rights to its
preclinical Huntington's disease program from Sirna Therapeutics, a wholly
owned subsidiary of Merck & Co., Inc. and former collaborator on the
program. Sirna also assigned to Targeted Genetics a licensing agreement it
has with the University of Iowa that covers certain IP related to RNA
interference (RNAi) including AAV expressed RNAi.
-- In March 2008, the Company announced that dosing has been completed
for the Phase 1/2 clinical trial of tgAAC94 for the treatment of
inflammatory arthritis. The Company plans to report additional Phase 1/2
results during 2008 at the American Society of Gene Therapy (ASGT), the
European League Against Rheumatism (EULAR) and the American College of
Rheumatology (ACR) in May, June and October respectively. |
